Last reviewed · How we verify

NCT06766214

Attexis and tDCS for the Treatment of ADHD

Completed NA Last updated 27 February 2026
What this trial tests

NA trial testing transcranial direct current stimulation in ADHD in 30 participants. Completed in 24 February 2026.

Timeline
1 September 2024
Primary endpoint
21 November 2025
24 February 2026

Quick facts

Lead sponsorUniversity of Regensburg
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment30
Start date1 September 2024
Primary completion21 November 2025
Estimated completion24 February 2026
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University of Regensburg

Who can join

Adults 18 to 65, any sex, with ADHD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized controlled two-arm study (RCT) will be conducted. It is planned to randomly assign eligible patients who receive a three-month access to the psychotherapeutic program (Attexis) to either an additional verum-tDCS or placebo-tDCS condition.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Home-based tDCS as an add-on to digital cognitive behavioral therapy application (dCBT app) in adults with ADHD: A sham-controlled randomized pilot study
    Kerkel K, Reissmann A, Treml L, Schecklmann M, et al · · 2026 · DOI 10.64898/2026.05.21.26353771

Verify or expand the search:

Other trials of transcranial direct current stimulation

Trials testing the same drug.

Other recruiting trials for ADHD

Currently open trials in the same condition.

Other University of Regensburg trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06766214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing